HomeCompareTCPFF vs PFE

TCPFF vs PFE: Dividend Comparison 2026

TCPFF yields 1.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCPFF wins by $30.21M in total portfolio value
10 years
TCPFF
TCPFF
● Live price
1.67%
Share price
$0.35
Annual div
$0.01
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.26M
Annual income
$27,136,237.35
Full TCPFF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TCPFF vs PFE

📍 TCPFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCPFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCPFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCPFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCPFF
Annual income on $10K today (after 15% tax)
$142.03/yr
After 10yr DRIP, annual income (after tax)
$23,065,801.75/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TCPFF beats the other by $23,043,481.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCPFF + PFE for your $10,000?

TCPFF: 50%PFE: 50%
100% PFE50/50100% TCPFF
Portfolio after 10yr
$15.15M
Annual income
$13,581,248.03/yr
Blended yield
89.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TCPFF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCPFF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCPFFPFE
Forward yield1.67%6.13%
Annual dividend / share$0.01$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$30.26M$49.6K
Annual income after 10y$27,136,237.35$26,258.71
Total dividends collected$29.99M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: TCPFF vs PFE ($10,000, DRIP)

YearTCPFF PortfolioTCPFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,034$334.18$9,153$693.39+$1.9KTCPFF
2$12,496$689.24$8,593$849.25+$3.9KTCPFF
3$14,829$1,458.95$8,336$1,066.78+$6.5KTCPFF
4$19,104$3,236.30$8,437$1,384.80+$10.7KTCPFF
5$28,234$7,792.73$9,013$1,875.40+$19.2KTCPFF
6$51,737$21,527.08$10,306$2,680.72+$41.4KTCPFF
7$129,092$73,733.55$12,820$4,101.38+$116.3KTCPFF
8$482,010$343,881.27$17,673$6,826.70+$464.3KTCPFF
9$2,915,745$2,399,993.83$27,543$12,591.86+$2.89MTCPFF
10$30,256,084$27,136,237.35$49,560$26,258.71+$30.21MTCPFF

TCPFF vs PFE: Complete Analysis 2026

TCPFFStock

True Corporation Public Company Limited, together with its subsidiaries, engages in the telecommunications and diversified communications industries in Thailand. The company operates through TrueMove H, TrueOnline, and TrueVisions segments. It offers mobile, broadband Internet, Wi-Fi, content and media, television, and digital platforms and solutions. The company is also involved in entertainment, mobile equipment lessor, program production, non-government telecommunication, artist management and related, Internet services provider and distributor, and marketing management activities. In addition, it operates news channel; and provides business solutions, online digital media services on website and telecommunication devices, distribution center services, consultancy and management services related to logistics, advertising sale and agency services, wireless telecommunication services, pay television via cable system, and football club and related activities management services. Further, the company operates as a content provider; designs, develops, produces, and sells software products; and offers data analytics and digital solutions, and hospitality technology, as well as business process outsourcing services in technical service, marketing, and customer relations. The company was formerly known as TelecomAsia Corporation Public Company Limited and changed its name to True Corporation Public Company Limited in April 2004. True Corporation Public Company Limited was incorporated in 1990 and is headquartered in Bangkok, Thailand.

Full TCPFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TCPFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCPFF vs SCHDTCPFF vs JEPITCPFF vs OTCPFF vs KOTCPFF vs MAINTCPFF vs JNJTCPFF vs MRKTCPFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.